Press Releases - Ipsen US

March 2, 2023

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

US

Ipsen completes acquisition of Albireo – Press Release – 03-23.pdf

January 20, 2023

Ipsen presents Phase III NAPOLI 3 trial of Onivyde® regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI

US

Ipsen NAPOLI 3 Phase III Press Release 01-2023.pdf

December 23, 2022

Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva

US

November 9, 2022

Onivyde® regimen demonstrated statistically significant improvement in overall survival in previously untreated metastatic pancreatic ductal adenocarcinoma

US

November 3, 2022

Ipsen to Highlight Expanded Oncology Portfolio and Advances in Follicular Lymphoma Research at ASH 2022

US

October 25, 2022

Ipsen statement on updated timeline for palovarotene FDA Advisory Committee meeting

US

August 12, 2022

Ipsen completes acquisition of Epizyme expanding its portfolio in oncology

US

June 29, 2022

Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission

US

June 27, 2022

Ipsen to acquire Epizyme, expanding its portfolio in oncology

US

April 20, 2022

IPSEN SPONSORS PANCREATIC CANCER ACTION NETWORK’S PURPLESTRIDE WALK

US

December 17, 2021

Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset evaluated in Primary Biliary Cholangitis, as part of a long-term global partnership

US

November 3, 2021

Ipsen appoints Stewart Campbell Executive Vice President and President of North America

US

October 18, 2021

Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3

US

August 13, 2021

Ipsen announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses

US

August 2, 2021

Ipsen and Exicure enter into exclusive collaboration targeting rare neurodegenerative disorders

US

Ipsen_Exicure_collaboration_2-August-2021.pdf

July 27, 2021

Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway

US

July 15, 2021

Ipsen and IRLAB enter exclusive worldwide licensing agreement aimed to improve the lives of people living with Parkinson’s disease

US

May 28, 2021

Ipsen confirms U.S. FDA accepts New Drug Application for palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)

US

December 1, 2020

Ipsen receives FDA Fast Track designation for investigational irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (SCLC)

US

Ipsen_Onivyde FDA Fast Track_ENG.pdf

September 10, 2020

Ipsen to present new insights at ASBMR for potential treatment of ultra-rare disease fibrodysplasia ossificans progressiva (FOP), including global Phase III MOVE trial results

US

Curtain-Raiser-Ipsen-ASBMR-2020.pdf

August 25, 2020

Ipsen to present results from MOVE, the first global Phase III trial in fibrodysplasia ossificans progressiva (FOP), at ASBMR 2020 annual meeting

US

Ipsen_Global-media-release_MOVE_EN.pdf

July 10, 2020

Ipsen Announces Updated Indication for Dysport® (abobotulinumtoxinA) for the Treatment of Spasticity in Children

US

June 30, 2020

Ipsen presents Phase I/II clinical data evaluating liposomal irinotecan (Onivyde®) as an investigational first-line combination treatment for metastatic pancreatic cancer at the ESMO World Congress on Gastrointestinal Cancer

US

March 11, 2020

Multi-National PRESTO Study Presented by ENETS with Simultaneous Publication in Advances in Therapy

US

SMD-US-003889_SomatulineDepot_PressRelease.pdf

September 26, 2019

Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Children, Excluding Cerebral Palsy

US

Dysport-PULS-Approval-Press-Release_9.26.19_FINAL.pdf

September 8, 2019

Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer

US

Ipsen_Onivyde_1st_Line World_GI_Data_Presentation_Press_Release.pdf

July 5, 2019

Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress on Gastrointestinal Cancer

US

Ipsen_Onivyde_1st_Line World_GI_Data_Presentation_Press_Release.pdf

June 24, 2019

Ipsen Announces U.S. FDA Approval for Newly Designed Pre-Filled Syringe for Somatuline® Depot (lanreotide)

US

Ipsen_SD_NDS_Approval_Press_Release_6.24.19.pdf

June 20, 2019

Ipsen Celebrates Opening of New Cambridge Headquarters with Day of Service

US

Grand_Opening_Day_of_Service_Release_6.19.19.pdf

October 21, 2018

Ipsen Presents Real-World Pancreatic Cancer Data on ONIVYDE® at the European Society for Medical Oncology (ESMO) 2018 Annual Congress

US

NON-US-00681_Ipsen-ESMO-Data-Release_10.20.18-FINAL.pdf

October 5, 2018

Ipsen Presents Data on Somatuline® Depot at the North American Neuroendocrine Tumor Society (NANETS) Annual Symposium

US

October 3, 2018

Ipsen Joins Biotechnology Innovation Organization (BIO) To Advance Growth and Innovation

US

June 7, 2018

Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts

US

April 23, 2018

Ipsen Announces Efficacy and Safety Data for Dysport® (abobotulinumtoxinA) Across Multiple Therapeutic Uses at the 2018 Annual Meeting of the American Academy of Neurology

US

February 15, 2018

Ipsen Announces Dysport® (abobotulinumtoxinA) Data Presentations Highlighting Duration of Response and Potential Benefit of Repeated Treatment in Spasticity

US

January 17, 2018

Ipsen to Present Data at ASCO GI 2018, Including New Post-Hoc Analyses from ONIVYDE® (irinotecan liposome injection) Phase 3 NAPOLI-1 Trial

US

October 12, 2017

Ipsen Announces Five Poster Presentations of Dysport® (abobotulinumtoxinA) Data at the 2017 American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly

US

Choose your location: